share_log

Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments

Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments

Jasper Therapeutics公佈2024年第一季度財務業績和近期公司發展
Jasper Therapeutics ·  05/14 12:00

REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced results for the fiscal quarter ended March 31, 2024, and reported recent corporate developments.

加利福尼亞州雷德伍德城,2024年5月14日(GLOBE NEWSWIRE)——Jasper Therapeutics, Inc.(納斯達克股票代碼:JSPR)(賈斯珀),一家臨床階段的生物技術公司,專注於開發briquilimab,這是一種靶向C-kit(CD117)的新型抗體療法,用於治療慢性自發性蕁麻疹(CSU)和慢性誘發性蕁麻疹(CindU)等肥大細胞驅動的疾病,今天公佈了截至2024年3月31日的財季業績,並報告了最近的公司發展。

"We have continued to make strong progress advancing briquilimab during the first few months of the year," said Ronald Martell, President and Chief Executive Officer of Jasper. "The BEACON and SPOTLIGHT studies in chronic urticarias are rapidly enrolling patients and we remain on track to disclose initial data from the studies in the third quarter of 2024 and second half of 2024, respectively. In addition, we recently announced our intention to advance briquilimab into clinical development in asthma, an indication in which we believe mast cell depletion via c-Kit inhibition has the potential to significantly impact disease control across all subtypes of the disease. With multiple clinical data readouts on the horizon in addition to the launch of our asthma development program, we are looking forward to an exciting and milestone rich second half of the year."

賈斯珀總裁兼首席執行官羅納德·馬爹利表示:“在今年的前幾個月,我們在推進briquilimab方面繼續取得強勁進展。”“針對慢性蕁麻疹的BEACON和SPOTLIGHT研究正在迅速招收患者,我們仍有望分別在2024年第三季度和2024年下半年披露這些研究的初步數據。此外,我們最近宣佈打算將briquilimab推進哮喘臨床開發,我們認爲通過C-kit抑制導致的肥大細胞消耗有可能對該疾病所有亞型的疾病控制產生重大影響。除了哮喘開發計劃的啓動外,還有多份臨床數據即將發佈,我們期待下半年有一個激動人心且里程碑豐富。”

Highlights for First Quarter 2024 and Recent Weeks

2024年第一季度和最近幾周的亮點

  • Enrolling in the third cohort (80mg, Q8W) of the Company's Phase 1b/2a BEACON study of subcutaneous briquilimab in CSU, and, as of May 13th, 2024, the Company is cleared for enrollment in the fourth cohort (120mg, Q8W). The BEACON study is a dose escalation trial evaluating repeat doses of subcutaneous briquilimab in adult CSU patients who remain symptomatic after treatment with, or who cannot tolerate, omalizumab. Jasper has opened 25 clinical sites across the U.S. and EU to date. Jasper anticipates reporting preliminary data from the study in the third quarter of 2024.
  • 報名參加該公司對科羅拉多州立大學皮下布里曲利單抗的1b/2a期BEACON研究的第三組(80mg,Q8W),截至5月13日第四,2024年,公司獲准加入第四組(120mg,Q8W)。BEACON研究是一項劑量遞增試驗,評估了在接受奧馬珠單抗治療後仍有症狀或無法耐受的科羅拉多州立大學成年患者中重複使用皮下布里曲利單抗的劑量。迄今爲止,賈斯珀已在美國和歐盟開設了25個臨床中心。賈斯珀預計將在2024年第三季度報告該研究的初步數據。
  • Completed enrollment in the first cohort (40mg) of the Company's Phase 1b/2a SPOTLIGHT clinical study of subcutaneous briquilimab for the treatment of CIndU, and, as of May 13th, 2024, the Company is enrolling in the second cohort (120mg). The SPOTLIGHT study is evaluating a single administration of subcutaneous briquilimab in adult patients with cold urticaria (ColdU) or symptomatic dermographism (SD). Jasper anticipates reporting preliminary data from the SPOTLIGHT study in the second half of 2024.
  • 完成了該公司皮下briquilimab治療CindU的1b/2a期SPOTLIGHT臨床研究的第一個隊列(40mg)的入組(40mg),截至5月13日第四,2024年,該公司正在招收第二批學員(120mg)。SPOTLIGHT研究正在評估對感冒性蕁麻疹(ColDU)或有症狀的皮膚造影(SD)的成年患者單次皮下注射briquilimab。賈斯珀預計將在2024年下半年報告SPOTLIGHT研究的初步數據。
  • Announced expansion of the Company's mast cell portfolio with a new briquilimab development program in asthma. Jasper expects to begin enrolling patients in a Phase 1b/2a study in asthma patients in the fourth quarter of 2024.
  • 宣佈通過一項新的briquilimab哮喘開發計劃,擴大公司的肥大細胞產品組合。賈斯珀預計將於2024年第四季度開始招收患者參加針對哮喘患者的1b/2a期研究。
  • Jasper is hosting a KOL webinar on the potential of briquilimab in asthma on Monday, May 20, 2024, at 8:00 a.m. EST. The event will feature Prof. Joshua Boyce, M.D., the Albert L. Sheffer Professor of Medicine in the Field of Allergic Diseases at Harvard Medical School in Boston, Massachusetts. The Company will also be sharing preclinical data supporting development of briquilimab at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) 2024 Annual Meeting.
  • 賈斯珀將於美國東部標準時間2024年5月20日星期一上午8點舉辦一場關於briquilimab在哮喘中的潛力的KOL網絡研討會。該活動將邀請馬薩諸塞州波士頓哈佛醫學院過敏性疾病領域的艾伯特·謝弗醫學教授約書亞·博伊斯醫學博士參加。該公司還將在即將舉行的歐洲過敏與臨床免疫學學會(EAACI)2024年年會上分享支持briquilimab開發的臨床前數據。
  • Completed enrollment into the third cohort (0.6 mg/kg) of the Phase 1 trial of briquilimab as second-line therapy in subjects with lower to intermediate risk myelodysplastic syndromes (LR-MDS). The Company now anticipates reporting initial data from this study in the second half of 2024.
  • briquilimab作爲二線療法,完成了對中低風險骨髓增生異常綜合徵(LR-MDS)受試者的1期試驗第三組(0.6 mg/kg)的入組。該公司現在預計將在2024年下半年報告這項研究的初步數據。
  • Announced additional positive Phase 1b/2a data on briquilimab as a conditioning agent in the treatment of Chronic Granulomatous Disease (CGD) at the 2024 Clinical Immunological Society (CIS) Annual Meeting held on May 3, 2024. The ongoing investigator-initiated Phase 1b/2a clinical trial is evaluating a conditioning regimen that includes intravenous briquilimab as a potential treatment for CGD patients. Data from the study show that briquilimab infusion has a promising safety profile and appears to be well-tolerated in patients with CGD, with five out of six assessable patients treated having achieved full donor engraftment.
  • 在2024年5月3日舉行的2024年臨床免疫學會(CIS)年會上,公佈了更多關於布里曲利單抗作爲治療慢性肉芽腫病(CGD)的調理劑的1b/2a期陽性數據。正在進行的研究者發起的1b/2a期臨床試驗正在評估一種調理方案,該方案包括靜脈注射briquilimab作爲CGD患者的潛在治療方法。該研究的數據表明,briquilimab輸液具有良好的安全性,並且對CGD患者的耐受性似乎良好,接受治療的可評估患者中有六分之五已經實現了完全的供體移植。
  • Successfully completed an underwritten offering of 3,900,000 shares of common stock for gross proceeds of approximately $50 million in February 2024, which extends Jasper's cash runway through the third quarter of 2025.
  • 2024年2月成功完成了3900,000股普通股的承銷發行,總收益約爲5000萬美元,這使賈斯珀的現金流延至2025年第三季度。

First Quarter Fiscal 2024 Financial Results

2024財年第一季度財務業績

  • Cash and cash equivalents as of March 31, 2024, totaled $118.5 million.
  • Research and development expenses for the quarter ended March 31, 2024, were $10.3 million, including stock-based compensation expenses of $0.3 million.
  • General and administrative expenses for the quarter ended March 31, 2024, were $4.8 million, including stock-based compensation expenses of $0.8 million.
  • Jasper reported a net loss of $13.7 million, or basic and diluted net loss per share attributable to common stockholders of $1.03, for the quarter ended March 31, 2024.
  • 截至2024年3月31日,現金及現金等價物總額爲1.185億美元。
  • 截至2024年3月31日的季度研發費用爲1,030萬美元,其中包括30萬美元的股票薪酬支出。
  • 截至2024年3月31日的季度的一般和管理費用爲480萬美元,其中包括80萬美元的股票薪酬支出。
  • 賈斯珀報告稱,截至2024年3月31日的季度淨虧損爲1,370萬美元,即歸屬於普通股股東的基本和攤薄後每股淨虧損1.03美元。

Inducement Grant

激勵補助金

On May 13, 2024, four new employees were awarded grants of options to purchase an aggregate of 43,600 shares of voting common stock (the Options). Each Option was granted pursuant to the Jasper Therapeutics, Inc. Amended and Restated 2022 Inducement Equity Incentive Plan, as approved by the compensation committee of Jasper's board of directors on March 14, 2022 and as amended and restated on June 2, 2023, and was granted as an inducement material to the applicable employee's employment with Jasper in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price of each Option is $20.76. Each Option will vest over four years, with 25% of the total number of shares vesting on the one year anniversary of the date of commencement of the applicable employee's employment with Jasper and 1/48th of the total number of shares subject to such Option vesting monthly thereafter, subject in each case to the employee's continued service to Jasper on each vesting date. Jasper is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

2024年5月13日,四名新員工獲得了購買總計43,600股有表決權的普通股(期權)的期權授予。每份期權都是根據Jasper Therapeutics, Inc.修訂和重述的2022年激勵股權激勵計劃授予的,該計劃經賈斯珀董事會薪酬委員會於2022年3月14日批准,並於2023年6月2日進行了修訂和重述,並根據納斯達克上市規則5635 (c) (4) 作爲相關員工在賈斯珀工作的激勵材料授予。每個期權的行使價爲20.76美元。每種期權將在四年內歸屬,在適用員工開始在賈斯珀工作一週年之日歸屬的股份總數的25%,此後每月歸屬於該期權的股份總數的1/48%,視員工在每個歸屬日期繼續爲賈斯珀服務而定。賈斯珀根據納斯達克上市規則5635(c)(4)提供這些信息。

About Briquilimab

關於 briquilimab

Briquilimab (formerly JSP191) is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria. Jasper is currently conducting clinical studies of briquilimab as a treatment in patients with CSU or with CIndU. Briquilimab is also currently in clinical studies as a treatment for patients with LR-MDS and as a conditioning agent for cell therapies for rare diseases. To date, briquilimab has a demonstrated efficacy and safety profile in more than 145 dosed participants and healthy volunteers, with clinical outcomes as a conditioning agent in severe combined immunodeficiency (SCID), AML, MDS, FA, and sickle cell disease (SCD).

Briquilimab(前身爲 JSP191)是一種靶向的糖基化單克隆抗體,可阻止幹細胞因子與細胞表面受體 C-kit(也稱爲 CD117)結合,從而抑制通過受體的信號傳導。這種抑制會干擾關鍵的存活信號,通過細胞凋亡導致肥大細胞消耗,從而消除肥大細胞驅動的疾病(例如慢性蕁麻疹)炎症反應的潛在來源。賈斯珀目前正在對briquilimab作爲科羅拉多州立大學或CinDU患者的治療藥物進行臨床研究。Briquilimab目前也在臨床研究中,它既是LR-MDS患者的治療方法,也是罕見疾病細胞療法的調理劑。迄今爲止,briquilimab在超過145名給藥參與者和健康志願者中具有顯著的療效和安全性,作爲重度聯合免疫缺陷(SCID)、急性髓細胞白血病、MDS、FA和鐮狀細胞病(SCD)的調理劑具有臨床療效。

About Jasper

關於賈斯珀

Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and lower to intermediate risk MDS and as a conditioning agent for stem cell transplants for rare diseases such as SCD, FA and SCID. To date, briquilimab has a demonstrated efficacy and safety profile in more than 145 dosed participants and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, AML, MDS, FA, and SCD. For more information, please visit us at www.jaspertherapeutics.com.

Jasper是一家處於臨床階段的生物技術公司,正在開發briquilimab,這是一種靶向 c-kit (CD117) 的單克隆抗體,用於治療慢性蕁麻疹和低至中等風險 MDS 等慢性肥大和幹細胞疾病,並作爲 SCD、FA 和 SCID 等罕見疾病幹細胞移植的調節劑。迄今爲止,briquilimab在超過145名給藥參與者和健康志願者中已得到證實的療效和安全性,作爲SCID、AML、MDS、FA和SCD的調理劑,其臨床結果爲調理劑。欲了解更多信息,請訪問我們的網站 www.jaspertherapeut

Forward-Looking Statements

前瞻性陳述

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab's potential, including with respect to its potential in mast cell driven diseases such as CSU and CIndU and LR-MDS; Jasper's expectations regarding milestones in the second half of the year; Jasper's expectations regarding its Phase 1b/2a study of subcutaneous briquilimab in CSU, including the site locations, expected enrollment and expected timing for reporting preliminary data; Jasper's expectations regarding its Phase 1b/2a study of subcutaneous briquilimab in CindU, including the expected enrollment and expected timing for reporting preliminary data; Jasper's expectations regarding its briquilimab development program in asthma and its Phase 1b/2a study in asthma patients, including expected timing of enrollment; Jasper's expectations regarding timing of initial data from its Phase 1 trial of briquilimab as second-line therapy in subjects with lower to intermediate risk myelodysplastic syndromes; Jasper's cash runway; and statements regarding intravenous briquilimab as a potential treatment for CGD patients, including its promising safety profile. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper's product candidates may not be beneficial to patients or successfully commercialized; patients' willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper's business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper's business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper's assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

就1995年《美國私人證券訴訟改革法》的安全港條款而言,本新聞稿中包含的某些非歷史事實的陳述是前瞻性陳述。前瞻性陳述有時伴隨着諸如 “相信”、“可能”、“將”、“估計”、“繼續”、“預測”、“打算”、“預期”、“應該”、“將”、“計劃”、“潛在”、“看來”、“尋找”、“未來”、“展望” 等詞語以及預測或表明未來事件或趨勢或不是歷史問題陳述的類似表達。這些前瞻性陳述包括但不限於有關briquilimab潛力的陳述,包括有關其在肥大細胞驅動疾病中的潛力的陳述,例如科羅拉多州立大學、CindU和LR-MDS;賈斯珀對下半年裏程碑的預期;賈斯珀對科羅拉多州立大學皮下布里曲利單抗的1b/2a期研究,包括研究地點、預計入學時間和預計入學時間報告初步數據;賈斯珀對其皮下briquilimab的1b/2a期研究的期望CinDU,包括預期入組人數和預計報告初步數據的時間;賈斯珀對其哮喘briquilimab開發計劃及其針對哮喘患者的1b/2a期研究的預期,包括預期的入組時間;賈斯珀對布里曲利單抗作爲低至中等風險骨髓增生異常綜合徵受試者的二線療法的1期試驗初步數據的時機的預期;賈斯珀的現金流和聲明將靜脈注射briquilimab視爲CGD患者的潛在治療方法,包括其安全狀況令人鼓舞。這些陳述基於各種假設,無論是否在本新聞稿中提出,也基於賈斯珀當前的預期,不是對實際業績的預測。這些前瞻性陳述僅用於說明目的,無意用作擔保、保證、預測或明確的事實或概率陳述,投資者也不得依賴這些陳述作爲擔保、保證、預測或明確的事實或概率陳述。許多實際事件和情況都超出了賈斯珀的控制範圍。這些前瞻性陳述受許多風險和不確定性的影響,包括總體經濟、政治和商業狀況;賈斯珀開發的潛在候選產品可能無法在預期的時間表內或根本無法通過臨床開發取得進展或獲得所需的監管部門批准的風險;臨床試驗可能無法證實本新聞稿中描述或假設的任何安全性、效力或其他產品特徵的風險;賈斯珀無法成功上市或獲得市場認可的風險其候選產品;先前研究結果無法複製的風險;賈斯珀的候選產品可能無法使患者受益或無法成功商業化的風險;患者嘗試新療法的意願和醫生開這些療法的意願;競爭對賈斯珀業務的影響;賈斯珀賴以提供實驗室、臨床開發、製造和其他關鍵服務的第三方無法令人滿意地表現的風險;賈斯珀的風險 Per 的業務、運營、臨床發展計劃和時間表以及供應鏈可能會受到以下因素的不利影響:健康流行病的影響;賈斯珀無法爲其研究產品獲得和維持足夠的知識產權保護或侵犯他人知識產權保護的風險;以及賈斯珀向美國證券交易委員會提交的文件中不時指出的其他風險和不確定性,包括其截至2023年12月31日止年度的10-K表年度報告和隨後的表格季度報告 10-Q。如果這些風險中的任何一個成爲現實,或者賈斯珀的假設被證明不正確,則實際結果可能與這些前瞻性陳述所暗示的結果存在重大差異。儘管賈斯珀可能會選擇在未來的某個時候更新這些前瞻性陳述,但賈斯珀明確表示不承擔任何更新這些前瞻性陳述的義務。不應將這些前瞻性陳述視爲賈斯珀對本新聞稿發佈之日後任何日期的評估。因此,不應過分依賴前瞻性陳述。

Contacts:

聯繫人:

Joyce Allaire (investors)
LifeSci Advisors
617-435-6602
jallaire@lifesciadvisors.com

喬伊斯·阿萊爾(投資者)
生命科學顧問
617-435-6602
jallaire@lifesciadvisors.com

Alex Gray (investors)
Jasper Therapeutics
650-549-1454
agray@jaspertherapeutics.com

亞歷克斯·格雷(投資者)
賈斯珀療法
650-549-1454
agray@jaspertherapeutics.com

Lauren Barbiero (media)
Real Chemistry
646-564-2156
lbarbiero@realchemistry.com

勞倫·巴比羅(媒體)
真正的化學
646-564-2156
lbarbiero@realchemistry.com

--- tables to follow---

---需要關注的表格---

JASPER THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share data)
(unaudited)
Three Months Ended March 31,
2024 2023
Operating expenses
Research and development(1) $ 10,298 $ 9,805
General and administrative(1) 4,774 4,142
Total operating expenses 15,072 13,947
Loss from operations (15,072) (13,947)
Interest income 1,386 1,096
Change in fair value of earnout liability (20) (764)
Change in fair value of common stock warrant liability (575)
Other income (expense), net (22) (70)
Total other income, net 1,344 (313)
Net loss and comprehensive loss $ (13,728) $ (14,260)
Net loss per share attributable to common stockholders, basic and diluted $ (1.03) $ (1.62)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 13,334,900 8,787,756
(1) Amounts include non-cash stock based compensation expense as follows (in thousands):
Three Months Ended March 31,
2024 2023
Research and development $ 349 $ 468
General and administrative 820 799
Total $ 1,169 $ 1,267
賈斯珀療法公司
簡明的合併運營報表和綜合虧損
(以千計,股票和每股數據除外)
(未經審計)
截至3月31日的三個月
2024 2023
運營費用
研究和開發(1) $ 10,298 $ 9,805
一般和行政(1) 4,774 4,142
運營費用總額 15,072 13,947
運營損失 (15,072) (13,947)
利息收入 1,386 1,096
收益負債公允價值的變化 (20) (764)
普通股認股權證負債公允價值的變化 (575)
其他收入(支出),淨額 (22) (70)
其他收入總額,淨額 1,344 (313)
淨虧損和綜合虧損 $ (13,728) $ (14,260)
歸屬於普通股股東的每股淨虧損,基本虧損和攤薄後 $ (1.03) $ (1.62)
用於計算歸屬於普通股股東的每股淨虧損的加權平均股數,基本和攤薄後 13,334,900 8,787,756
(1) 金額包括非現金股票薪酬支出,如下所示(以千計):
截至3月31日的三個月
2024 2023
研究和開發 $ 349 $ 468
一般和行政 820 799
總計 $ 1,169 $ 1,267
JASPER THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)
March 31, December 31,
Assets 2024 2023
Current assets:
Cash and cash equivalents $ 118,475 $ 86,887
Prepaid expenses and other current assets 1,833 2,051
Total current assets 120,308 88,938
Property and equipment, net 2,464 2,727
Operating lease right-of-use assets 1,351 1,467
Restricted cash 417 417
Other non-current assets 1,423 1,343
Total assets $ 125,963 $ 94,892
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable $ 2,391 $ 4,149
Current portion of operating lease liabilities 1,000 972
Earnout liability 20 -
Accrued expenses and other current liabilities 5,505 7,253
Total current liabilities 8,916 12,374
Non-current portion of operating lease liabilities 1,553 1,814
Other non-current liabilities 2,264 2,264
Total liabilities 12,733 16,452
Commitments and contingencies
Stockholders' equity:
Preferred stock
Common stock 2 1
Additional paid-in capital 296,556 248,039
Accumulated deficit (183,328) (169,600)
Total stockholders' equity 113,230 78,440
Total liabilities and stockholders' equity $ 125,963 $ 94,892
賈斯珀療法公司
簡明的合併資產負債表
(以千計)
(未經審計)
3月31日 十二月三十一日
資產 2024 2023
流動資產:
現金和現金等價物 $ 118,475 $ 86,887
預付費用和其他流動資產 1,833 2,051
流動資產總額 120,308 88,938
財產和設備,淨額 2,464 2727
經營租賃使用權資產 1,351 1,467
受限制的現金 417 417
其他非流動資產 1,423 1,343
總資產 $ 125,963 $ 94,892
負債和股東權益
流動負債:
應付賬款 $ 2,391 $ 4,149
經營租賃負債的流動部分 1,000 972
盈利責任 20 -
應計費用和其他流動負債 5,505 7,253
流動負債總額 8,916 12,374
經營租賃負債的非流動部分 1,553 1,814
其他非流動負債 2,264 2,264
負債總額 12,733 16,452
承付款和意外開支
股東權益:
優先股
普通股 2 1
額外的實收資本 296,556 248,039
累計赤字 (183,328) (169,600)
股東權益總額 113,230 78,440
負債和股東權益總額 $ 125,963 $ 94,892

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論